Andreas Katsambas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andreas Katsambas has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
C Antoniou
1st Department of Dermatology, University of Athens School of Medicine, ‘Andreas Sygros’ Hospital, Athens, Greece
2 shared publications- Stamatios Gregoriou
Department of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, 16121 Athens, Greece
2 shared publications A Stratigos
1st Department of Dermatology, University of Athens School of Medicine, ‘Andreas Sygros’ Hospital, Athens, Greece
1 shared publicationAe Moustou
1st Department of Dermatology, University of Athens School of Medicine, ‘Andreas Sygros’ Hospital, Athens, Greece
1 shared publicationAj Stratigos
Department of Dermatology, University of Athens, School of Medicine, Andreas Sygros Hospital, Athens, Greece
1 shared publicationAlexander J Stratigos
Department of Dermatology, University of Athens School of Medicine, Andreas Sygros Hospital for Skin and Venereal Diseases, Athens, Greece
1 shared publication
Latest Publications
- 30 June 2011
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 37 (4) , 284-290
Methods of detection of circulating melanoma cells: A comparative overview
- 30 June 2011
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 37 (4) , 284-290
Methods of detection of circulating melanoma cells: A comparative overview
- 1 January 2010
- Published by Elsevier in Clinics in Dermatology
- Vol. 28 (1) , 17-23
Hormonal therapy for acne: why not as first line therapy? facts and controversies
- 1 January 2010
- Published by Elsevier in Clinics in Dermatology
- Vol. 28 (1) , 17-23
Hormonal therapy for acne: why not as first line therapy? facts and controversies
- 3 June 2009
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 23 (7) , 854-855
Palmoplantar pustulosis with arthro‐osteitis: successful treatment with etanercept and acitretin
- 3 June 2009
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 23 (7) , 854-855
Palmoplantar pustulosis with arthro‐osteitis: successful treatment with etanercept and acitretin
- 10 October 2008
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 22 (11) , 1281-1289
Pathogenesis of subacute cutaneous lupus erythematosus
Subacute cutaneous lupus erythematosus (SCLE) is a photosensitive form of lupus‐specific skin lesion that is strongly associated with the presence of anti‐Ro/SSA autoantibody. The pathogenesis of SCLE includes genetic, environmental and immunologic factors. Recent studies provide strong evidence for the involvement of innate and cell‐mediated immunity, underlying the important role of plasmacytoid dendritic cells, interferon‐α and antibody‐dependent cell cytotoxicity. In addition, a variety of cytokines, chemokines and adhesion molecules have been found to participate in the expansion phase of the autoimmune effector mechanisms. This article summarizes the recent immunological findings and reviews the current mechanisms which are implied in the development of the disease.
- 10 October 2008
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 22 (11) , 1281-1289
Pathogenesis of subacute cutaneous lupus erythematosus
Subacute cutaneous lupus erythematosus (SCLE) is a photosensitive form of lupus‐specific skin lesion that is strongly associated with the presence of anti‐Ro/SSA autoantibody. The pathogenesis of SCLE includes genetic, environmental and immunologic factors. Recent studies provide strong evidence for the involvement of innate and cell‐mediated immunity, underlying the important role of plasmacytoid dendritic cells, interferon‐α and antibody‐dependent cell cytotoxicity. In addition, a variety of cytokines, chemokines and adhesion molecules have been found to participate in the expansion phase of the autoimmune effector mechanisms. This article summarizes the recent immunological findings and reviews the current mechanisms which are implied in the development of the disease.
- 18 August 2008
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 22 (9) , 1110-1119
Sunscreens – what's important to know
The popularity of sunscreens dramatically increased since ultraviolet irradiation was implicated in the pathogenesis of skin cancer and skin ageing. The absorption properties, safety, photostability of different organic and inorganic filters are reviewed: para‐aminobenzoic acid, salicylates, cinnamates, benzophenones, butylmethoxydibenzoylmethane (Parsol 1789), drometrizole trisulphonic (Mexoryl XL), terephthalydene dicamphor sulphonic acid (Mexoryl SX), methylene bisbenzotriazol tetramethylbutylphenol (Tinasorb M), anisotriazine (Tinasorb S), titanium dioxide and zinc oxide. Furthermore, this review discusses the optimal methods for measuring the protection that a sunscreen offers, the role of sunscreen use in melanoma prevention and future trends in sunscreen filters development.
- 18 August 2008
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 22 (9) , 1110-1119
Sunscreens – what's important to know
The popularity of sunscreens dramatically increased since ultraviolet irradiation was implicated in the pathogenesis of skin cancer and skin ageing. The absorption properties, safety, photostability of different organic and inorganic filters are reviewed: para‐aminobenzoic acid, salicylates, cinnamates, benzophenones, butylmethoxydibenzoylmethane (Parsol 1789), drometrizole trisulphonic (Mexoryl XL), terephthalydene dicamphor sulphonic acid (Mexoryl SX), methylene bisbenzotriazol tetramethylbutylphenol (Tinasorb M), anisotriazine (Tinasorb S), titanium dioxide and zinc oxide. Furthermore, this review discusses the optimal methods for measuring the protection that a sunscreen offers, the role of sunscreen use in melanoma prevention and future trends in sunscreen filters development.
- 1 March 2008
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 21 (2) , 86-95
New and emerging treatments in dermatology: acne
Topical retinoids, benzoyl peroxide, azelaic acid, and topical and oral antibiotics remain the milestone of treatment for mild to moderate acne vulgaris. Oral isotretinoin is useful for the treatment of severe nodular acne, treatment-resistant acne, and acne with a risk of physical or psychological scarring. Hormonal treatment in female acne is useful in resistant or late-onset acne. With increasing concerns regarding teratogenicity of isotretinoin and increasing antibiotic resistance, there is a clear need for therapeutic alternatives to these long-used treatments. Research in the pathogenesis of acne has allowed for new therapies and future perspectives regarding acne to evolve. They include low-dose long-term isotretinoin regimens, insulin-sensitizing agents, 5alpha-reductase type 1 inhibitors, topical photodynamic therapy, new combination formulations, dietary interventions, and antiinflammatory agents such as lipoxygenase inhibitors.
- 1 March 2008
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 21 (2) , 86-95
New and emerging treatments in dermatology: acne
Topical retinoids, benzoyl peroxide, azelaic acid, and topical and oral antibiotics remain the milestone of treatment for mild to moderate acne vulgaris. Oral isotretinoin is useful for the treatment of severe nodular acne, treatment-resistant acne, and acne with a risk of physical or psychological scarring. Hormonal treatment in female acne is useful in resistant or late-onset acne. With increasing concerns regarding teratogenicity of isotretinoin and increasing antibiotic resistance, there is a clear need for therapeutic alternatives to these long-used treatments. Research in the pathogenesis of acne has allowed for new therapies and future perspectives regarding acne to evolve. They include low-dose long-term isotretinoin regimens, insulin-sensitizing agents, 5alpha-reductase type 1 inhibitors, topical photodynamic therapy, new combination formulations, dietary interventions, and antiinflammatory agents such as lipoxygenase inhibitors.
- 24 August 2007
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 6 (3) , 195-202
Hyperpigmentation and melasma
Summary: Facial and neck pigmentations are significant cosmetic problems. They are common in middle‐aged women, related to endogenous (hormones) and exogenous factors (cosmetics, perfumes, sun exposure), and often represent paramount causes of emotional distress. Although melasma is the most common cause of facial pigmentation, there are many other forms including drug‐induced and postinflammatory hyperpigmentation. We review pathogenesis, clinical and histopathological data, effect on quality of life, and treatment options in facial hyperpigmentation disorders.
- 24 August 2007
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 6 (3) , 195-202
Hyperpigmentation and melasma
Summary: Facial and neck pigmentations are significant cosmetic problems. They are common in middle‐aged women, related to endogenous (hormones) and exogenous factors (cosmetics, perfumes, sun exposure), and often represent paramount causes of emotional distress. Although melasma is the most common cause of facial pigmentation, there are many other forms including drug‐induced and postinflammatory hyperpigmentation. We review pathogenesis, clinical and histopathological data, effect on quality of life, and treatment options in facial hyperpigmentation disorders.
- 20 March 2007
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 6 (2) , 79-84
AIDS in pregnancy, part II: Treatment in the era of highly active antiretroviral therapy and management of obstetric, anesthetic, and pediatric issues.
- 20 March 2007
- Published by Wiley in SKINmed: Dermatology for the Clinician
- Vol. 6 (2) , 79-84
AIDS in pregnancy, part II: Treatment in the era of highly active antiretroviral therapy and management of obstetric, anesthetic, and pediatric issues.
- 22 December 2006
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 5 (4) , 303-308
Established treatments of skin hypermelanoses
Summary: Cutaneous hypermelanoses are frequently encountered conditions that can have severe adverse psychosocial and emotional effects on affected patients. Melasma, postinflammatory hyperpigmentation, drug‐induced pigmentation, and erythema dischromicum perstans are among the most common cutaneous disorders leading to acquired skin hyperpigmentation. The treatment of these disorders is often challenging and requires a great deal of patience from the patient and a wealth of experience and knowledge from the dermatologist. Current treatments include depigmenting agents, chemical peels, and lasers. The ideal bleaching agent has to fulfill certain pharmacologic criteria. It should have a potent bleaching effect with a rapid time of onset, carry no side effects, and lead to a permanent removal of undesired pigment. We review the established treatment approaches of cutaneous hyperpigmentation based on literature review and our personal experience.
- 22 December 2006
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 5 (4) , 303-308
Established treatments of skin hypermelanoses
Summary: Cutaneous hypermelanoses are frequently encountered conditions that can have severe adverse psychosocial and emotional effects on affected patients. Melasma, postinflammatory hyperpigmentation, drug‐induced pigmentation, and erythema dischromicum perstans are among the most common cutaneous disorders leading to acquired skin hyperpigmentation. The treatment of these disorders is often challenging and requires a great deal of patience from the patient and a wealth of experience and knowledge from the dermatologist. Current treatments include depigmenting agents, chemical peels, and lasers. The ideal bleaching agent has to fulfill certain pharmacologic criteria. It should have a potent bleaching effect with a rapid time of onset, carry no side effects, and lead to a permanent removal of undesired pigment. We review the established treatment approaches of cutaneous hyperpigmentation based on literature review and our personal experience.
- 17 January 2006
- Published by Wiley in International Journal of Dermatology
- Vol. 45 (6) , 642-648
Polymorphic eruption of pregnancy
Polymorphic eruption of pregnancy (PEP) is a benign, self‐limiting, pruritic disorder of pregnancy, which usually affects the primigravida during the last trimester or immediately postpartum. Its pathogenesis is unclear and its clinical manifestations are variable, leading frequently to an incorrect diagnosis. In cases of PEP the histological findings are nonspecific and the laboratory results, including direct immunofluorescence (DIF) and indirect immunofluorescence (IIF), are negative. Polymorphic eruption of pregnancy is not associated with any fetal risk and symptomatic treatment is all that is usually required.In this review we present the clinical presentation of PEP and a differential diagnosis which defines PEP as a separate entity. We will also review all current data of possible etiologic factors, histologic and immunologic findings, prognosis and therapy.
- 17 January 2006
- Published by Wiley in International Journal of Dermatology
- Vol. 45 (6) , 642-648
Polymorphic eruption of pregnancy
Polymorphic eruption of pregnancy (PEP) is a benign, self‐limiting, pruritic disorder of pregnancy, which usually affects the primigravida during the last trimester or immediately postpartum. Its pathogenesis is unclear and its clinical manifestations are variable, leading frequently to an incorrect diagnosis. In cases of PEP the histological findings are nonspecific and the laboratory results, including direct immunofluorescence (DIF) and indirect immunofluorescence (IIF), are negative. Polymorphic eruption of pregnancy is not associated with any fetal risk and symptomatic treatment is all that is usually required.In this review we present the clinical presentation of PEP and a differential diagnosis which defines PEP as a separate entity. We will also review all current data of possible etiologic factors, histologic and immunologic findings, prognosis and therapy.